The biotech highlighted in today’s article is the kind of stock that the author would normally advise investors to stay away from. In this case, however, he acknowledges that “this company could be worth quite a lot in the future, if it plays its cards right.” He proceeds to detail the company’s most interesting product – an anti-aging product that he believes has the potential to take it from micro-cap to industry leader (and which is drawing in a number of wealthy investors). For more, CLICK HERE